Neovacs: Funding, Investors & Team (Sep 2026)
Neovacs, a company created in 1993 by Professor Daniel Zagury, a renowned immunologist and AIDS expert from the Pierre & Marie Curie University in Paris, is focused on developing therapeutic vaccines for AIDS, cancer, and auto-immune & allergic diseases. The company owns numerous patents and is known for its innovative approach in creating vaccines targeting human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). While monoclonal antibodies are commonly used to treat cytokine-related diseases, Neovacs' vaccines stimulate a natural polyclonal antibody response in patients, offering a different and potentially more effective treatment option.
Neovacs has raised $6.5M across 3 funding rounds on record, the most recent an undisclosed round of $1.4M announced in May 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Neovacs Company Profile and Key Stats
Latest funding round on record: May 2025.
Neovacs Funding Rounds
Neovacs raised $4.8M in an undisclosed round announced in Jun 2021.
3.6 years later, an undisclosed round of $260k was announced in Jan 2025.
4 months later, an undisclosed round of $1.4M was announced in May 2025.
Neovacs Founders and Leadership Team
No contact details are on record for this team yet.
Neovacs Funding Compared to Other Biotechnology Startups
Neovacs' latest round of $1.4M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Neovacs in Biotechnology and Paris
Companies Similar to Neovacs
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Neovacs Funding FAQs
What does Neovacs do?
Neovacs, a company created in 1993 by Professor Daniel Zagury, a renowned immunologist and AIDS expert from the Pierre & Marie Curie University in Paris, is focused on developing therapeutic vaccines for AIDS, cancer, and auto-immune & allergic diseases. The company owns numerous patents and is known for its innovative approach in creating vaccines targeting human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). While monoclonal antibodies are commonly used to treat cytokine-related diseases, Neovacs' vaccines stimulate a natural polyclonal antibody response in patients, offering a different and potentially more effective treatment option.
How much funding has Neovacs raised?
Neovacs has raised $6.5M across 3 rounds on record. The most recent is an undisclosed round of $1.4M announced in May 2025.
When did Neovacs last raise funding?
Neovacs' most recent funding round on record is an undisclosed round of $1.4M, announced in May 2025.
Who founded Neovacs?
FundedIQ lists Daniel Zagury (Founder) at Neovacs.
Who is the CEO of Neovacs?
Miguel Sieler is listed as CEO at Neovacs.
Where is Neovacs headquartered?
Neovacs is based in Paris, Ile-De-France, France.
How many employees does Neovacs have?
Neovacs is in the 11-50 employee band.
How does Neovacs' funding compare to other Biotechnology startups?
Neovacs' latest round of $1.4M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Neovacs Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Neovacs is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.